Market Research Logo

Otonomy Inc (OTIC) - Financial and Strategic SWOT Analysis Review

Otonomy Inc (OTIC) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s OTIPRIO is a FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses investigational candidates targeted at the treatment of patients with acute otitis media with tympanostomy tubes (phase 2); cisplatin-induced hearing loss (phase 2), tinnitus (phase 2), and Meniere's disease and other balance and hearing disorders (phase 3). Otonomy is also conducting a preclinical program on sensorineural hearing loss including age-related hearing loss. It employs its proprietary formulation technology that uses a thermosensitive gel and drug microparticles for enabling single dose treatment by a physician. Otonomy is headquartered in San Diego, California, the US.

Otonomy Inc Key Recent Developments

May 04,2017: Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update
Mar 02,2017: Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Jan 09,2017: Otonomy Provides Corporate and Product Pipeline Update
Nov 30,2016: Otonomy appoints new chief scientific officer
Nov 03,2016: Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company 5
Otonomy Inc - Key Facts 5
Otonomy Inc - Key Employees 6
Otonomy Inc - Key Employee Biographies 7
Otonomy Inc - Major Products and Services 9
Otonomy Inc - History 10
Otonomy Inc - Company Statement 11
Otonomy Inc - Locations And Subsidiaries 13
Head Office 13
Section 2 – Company Analysis 14
Otonomy Inc - Business Description 14
Otonomy Inc - SWOT Analysis 15
SWOT Analysis - Overview 15
Otonomy Inc - Strengths 15
Otonomy Inc - Weaknesses 16
Otonomy Inc - Opportunities 17
Otonomy Inc - Threats 18
Otonomy Inc - Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios - Capital Market Ratios 20
Financial Ratios - Annual Ratios 21
Performance Chart 23
Financial Performance 23
Financial Ratios - Interim Ratios 24
Financial Ratios - Ratio Charts 25
Section 4 – Company’s Lifesciences Financial Deals and Alliances 26
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 26
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 27
Otonomy Inc, Recent Deals Summary 28
Section 5 – Company’s Recent Developments 29
May 04, 2017: Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update 29
Mar 02, 2017: Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 31
Jan 09, 2017: Otonomy Provides Corporate and Product Pipeline Update 33
Nov 30, 2016: Otonomy appoints new chief scientific officer 35
Nov 03, 2016: Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update 36
Aug 04, 2016: Otonomy Reports Second Quarter 2016 Financial Results and Provides Corporate Update 39
May 09, 2016: Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update 42
Mar 07, 2016: Otonomy Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 44
Section 6 – Appendix 46
Methodology 46
Ratio Definitions 46
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Tables
Otonomy Inc, Key Facts 5
Otonomy Inc, Key Employees 6
Otonomy Inc, Key Employee Biographies 7
Otonomy Inc, Major Products and Services 9
Otonomy Inc, History 10
Otonomy Inc, Key Competitors 19
Otonomy Inc, Ratios based on current share price 20
Otonomy Inc, Annual Ratios 21
Otonomy Inc, Annual Ratios (Cont...1) 22
Otonomy Inc, Interim Ratios 24
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 26
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 27
Otonomy Inc, Recent Deals Summary 28
Currency Codes 46
Capital Market Ratios 46
Equity Ratios 47
Profitability Ratios 47
Cost Ratios 48
Liquidity Ratios 48
Leverage Ratios 49
Efficiency Ratios 49
List of Figuress
Otonomy Inc, Performance Chart (2012 - 2016)
Otonomy Inc, Ratio Charts
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report